106 related articles for article (PubMed ID: 18296466)
21. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis.
Dormer RL; Harris CM; Clark Z; Pereira MM; Doull IJ; Norez C; Becq F; McPherson MA
Thorax; 2005 Jan; 60(1):55-9. PubMed ID: 15618584
[TBL] [Abstract][Full Text] [Related]
22. [Advances in researches on the onset and duration of the action of sildenafil].
Wang HP; Pu XY
Zhonghua Nan Ke Xue; 2005 May; 11(5):392-5. PubMed ID: 15934467
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations--the patient should be given the opportunity to try out all three].
Ströberg P; Hedelin H; Ljunggren C
Lakartidningen; 2006 Apr 5-11; 103(14):1107-8, 1110-1. PubMed ID: 16681094
[No Abstract] [Full Text] [Related]
24. Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in healthy male subjects.
Wensing G; Bauer R; Unger S; Rohde G; Heinig R
Int J Clin Pharmacol Ther; 2006 May; 44(5):216-24. PubMed ID: 16724576
[TBL] [Abstract][Full Text] [Related]
25. The postmortem distribution of vardenafil (Levitra) in an aviation accident victim with an unusually high blood concentration.
Johnson RD; Lewis RJ; Angier MK
J Anal Toxicol; 2007; 31(6):328-33. PubMed ID: 17725878
[TBL] [Abstract][Full Text] [Related]
26. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
[No Abstract] [Full Text] [Related]
27. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype.
Shon JH; Ku HY; Bae SY; Oh MK; Yeo CW; Bae SK; Shin JG
Pharmacogenet Genomics; 2011 Dec; 21(12):820-8. PubMed ID: 21934637
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice.
Lubamba B; Huaux F; Lebacq J; Marbaix E; Dhooghe B; Panin N; Wallemacq P; Leal T
J Cyst Fibros; 2012 Jul; 11(4):266-73. PubMed ID: 22503062
[TBL] [Abstract][Full Text] [Related]
29. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
30. Vardenafil allows successful intercourse initiated rapidly after dosing in Japanese patients with diabetes mellitus and erectile dysfunction.
Nagao K; Kobayashi H; Fujikawa K; Tachibana T; Iwamoto Y; Ishii N; Turek PJ; Brant WO; Kamidono S
J Sex Med; 2009 Oct; 6(10):2851-7. PubMed ID: 19732311
[TBL] [Abstract][Full Text] [Related]
31. [Birthday of a "potency pill". Helmut Newton celebrates posthumously likewise].
Keil TU
MMW Fortschr Med; 2004 Jul; 146(29-30):61. PubMed ID: 15540567
[No Abstract] [Full Text] [Related]
32. Therapy of ED: PDE-5 Inhibitors.
Shabsigh R
Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
[TBL] [Abstract][Full Text] [Related]
33. [Time effect window of sildenafil for the treatment of erectile dysfunction].
Zhang B; Qi T
Zhonghua Nan Ke Xue; 2005 Apr; 11(4):317-9. PubMed ID: 15921268
[TBL] [Abstract][Full Text] [Related]
34. Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms.
Noel S; Panin N; Beka M; Dhooghe B; Huaux F; Leal T
Clin Sci (Lond); 2017 Jun; 131(11):1107-1121. PubMed ID: 28196856
[TBL] [Abstract][Full Text] [Related]
35. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
36. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
38. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.
Sperling H; Gittelman M; Norenberg C; Ulbrich E; Ewald S
J Sex Med; 2011 Jan; 8(1):261-71. PubMed ID: 20807322
[TBL] [Abstract][Full Text] [Related]
40. Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis.
Huaux F; Noel S; Dhooghe B; Panin N; Lo Re S; Lison D; Wallemacq P; Marbaix E; Scholte BJ; Lebecque P; Leal T
PLoS One; 2013; 8(5):e64341. PubMed ID: 23734196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
